gdc
FDA Approvals, News & UpdatesLung CancerNewsworthy

Imfinzi First Drug Approved to Reduce Cancer Progression in Stage III Lung Cancer

November 2018 Volume 4 – Lung Cancer

In February 2018, the FDA approved Imfinzi (durvalumab; from AstraZeneca), a PD-L1 inhibitor, for the treatment of patients with stage III non–small-cell lung cancer (NSCLC) that cannot be removed by surgery (unresectable) and did not progress after chemoradiation.

“This is the first treatment approved for stage III unresectable non-small cell lung cancer to reduce the risk of the cancer progressing, when the cancer has not worsened after chemoradiation,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

“Although a small number of patients may be cured with the chemoradiation, the cancer may eventually progress. Patients now have an approved therapy that has been shown to keep the cancer from progressing for a longer time after chemoradiation,” Dr Pazdur added.

In clinical trials, patients who received Imfinzi had an average of 16.8 months without cancer progression versus 5.6 months with placebo. The average duration of survival without disease progression was 16.8 months with Imfinzi versus 5.6 months with placebo.

The common side effects associated with Imfinzi in patients with unresectable stage III NSCLC include cough, fatigue, pneumonitis, upper respiratory tract infections, dyspnea, and rash.

Recommended For You
FDA Approvals, News & UpdatesLeukemia
Tibsovo Approved for First-Line Treatment of Patients with Acute Myeloid Leukemia and IDH1 Mutation
In May 2019, the FDA approved Tibsovo for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) and an IDH1 mutation, or for patients with AML who are unable to use intensive chemotherapy.
Bladder CancerFDA Approvals, News & Updates
Balversa First Targeted Drug Approved for Metastatic Bladder Cancer with FGFR Genetic Alterations
In April 2019, the FDA approved Balversa, an FGFR kinase inhibitor, for the treatment of adults with advanced or metastatic bladder cancer and an FGFR genetic alteration, as determined by an FDA-approved diagnostic test. This is the first FDA-approved targeted drug for patients with this specific genetic mutation.
Last modified: December 11, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country